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ABSTRACT 
Objective: Rapid and inconsistent gastrointestinal tract (GIT) transit could result in reduced drug efficiency and the need for frequent dose 
administration, which usually result in patients’ incompliance. Ranitidine hydrochloride (RH), as a model drug is freely soluble, moisture sensitive 
drug with a short biological half-life (~2.5-3 h) and narrow absorption window in the initial part of the small intestine. The present study aimed to 
develop ranitidine floating multi-particulates (RFM) using melt granulation technique and investigation of the effect of lipids and additives on the 
physicochemical properties.  
Methods: RFM were prepared using Compritol® 888 ATO, glyceryl behenate, Cutina® HR, Cutina® GMS, hydrogenated castor oil, glyceryl 
monostearate, and beeswax as lipids and ethyl cellulose, Povidone® K 90 and Aerosil® 200 as release modifiers. The effect of the preparation method 
and additives, as well as storage for 6 mo at 40 °C, on floating and release characteristics were evaluated.  
Results: Size distribution indicated that the prepared formulations exhibited reasonably small floating micro particulates; more than 90% of the 
prepared microparticles were less than 710 µm. Hausner ratios and Carr’s compressibility indices ranged from 1.17 to 1.29% and 14.54 to 22.4 %, 
respectively, and the angle of repose values was ≤40 °, indicating good flow properties. RFM containing Compritol® showed a relatively higher release 
properties compared to hydrogenated castor oil. Increasing the proportion of the fatty component was accompanied by retardation in RH release. 
The tested additives (PVP, ethyl cellulose, Aerosil®) resulted in different degrees of retardation of drug release. The percent-floating of RFM was 
almost 100% in all formulations with the exception of formulations prepared using glyceryl monostearate. FT-IR and DSC studies indicated the 
compatibility of the excipients with RH. Stability results revealed an insignificant change in RFM properties over 6 mo. 
Conclusion: The prepared microparticles exhibited optimum particle size, good compressibility, and flow properties. RFM containing Compritol® 
showed a relatively higher release properties compared to hydrogenated castor oil. Increasing the proportion of the fatty component was 
accompanied by retardation in RH release. The percent-floating of RFM was almost 100% in most formulations. FT-IR and DSC indicated good 
compatibility of the excipients with RH and insignificant change in RFM properties over 6 mo’s storage. 
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INTRODUCTION 
Although tablets are widely used as a dosage form for several 
advantages, some drugs are not appropriately formulated as tablets. 
This may be due to poor bioavailability of some drugs, resulting from 
incomplete absorption in the gastrointestinal tract (GIT) or such 
drugs are suffering from narrow absorption window in the upper GIT. 
Accordingly, rapid and inconsistent GIT transit could result in 
reduced drug efficiency and thereby increase the need for frequent 
dose administration, resulting in patients’ incompliance. Ranitidine 
hydrochloride (RH) is freely soluble, moisture sensitive drug with a 
short biological half-life (~2.5-3 h) and limited absorption from the 
initial part of the small intestine and shows 50% absolute 
bioavailability [1, 2], and therefore, is a good candidate representing 
such class of drugs.  
The pharmaceutical research attempted to develop gastro-retentive 
dosage forms (GRDF) to prolong the gastric residence time of this 
class of drugs, and hence decreasing dose frequency [3]. One of the 
proposed mechanisms to achieve such objective is the low-density 
GRDF, which remains buoyant above the gastric secretions for 
sufficient time to ensure sustained release of the drug [4, 5].  
Melt granulation is one of the most widely applied processing 
techniques in the pharmaceutical manufacturing operations, which 
has been successfully applied for the formulation of GRDF, e. g. [6]. 
Melt granulation is a process by which granules are obtained by the 
addition of either a molten binder or a solid binder which melts 
during the process. It is also called melt agglomeration and 
thermoplastic granulation [7]. The absence of water in the 
agglomeration process makes this approach quite valuable for 
moisture-sensitive and thermolabile materials [8]. Due to the inert 
nature of binders used in this technique, formulations are expected to 
be more stable and less sensitive to pH change.  
Among the systems formulated by melt granulation, multi-particulate 
systems are used most commonly and can offer many unique 
advantages. Compared to single-unit dosage forms, such as matrix 
tablets, multi-particulate dosage forms distribute evenly in the GI track 
and can release drug substances in a uniform and continuous manner. 
They offer both formulation flexibility and good in vivo performance [9]. 
Multiparticulate dosage forms can also avoid dose dumping, minimize 
unit to unit variation, include particles with different release rates in 
one drug product, offer more reproducible release due to less variation 
in GIT transit time, reduce variation due to GIT condition or food effect 
and minimize GIT irritation [10]. Ranitidine hydrochloride was 
considered a good candidate for formulation in gastro-retentive 
sustained release floating micro particulates because of its narrow 
absorption window, as it is mainly absorbed in the proximal areas of the 
gastrointestinal tract [11, 12]. Hence, conventional sustained-release 
dosage form reaches the colon, where it gets metabolized, resulting in 
low absorption and poor bioavailability (52%) [1, 2].  
Therefore, the aims of this study were a) to develop ranitidine 
hydrochloride floating multi-particulates using melt granulation 
technique under different formulation conditions and b) to study the 
different factors affecting the physicochemical properties of the 
prepared ranitidine micro particulates.  
MATERIALS AND METHODS 
Materials 
Ranitidine hydrochloride (RH) (SMS pharmaceuticals, India); 
povidone K 90 (BASF, Germany); Compritol® 888 ATO and glyceryl 
behenate (Gattefosse, Saint-Priest, France); Aerosil® 200, Cutina® HR, 
hydrogenated castor oil and Cutina® GMS, and glyceryl monostearate 
(Cognis, France); beeswax (Kahil, India). All other reagents were 
analytical reagent grade. 
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Table 1: Formulation ingredients of ranitidine hydrochloride floating micro particulates (mg) 
Formulation 
 
Ranitidine 
HCl 
Compritol 888 
ATO 
Cutina 
HR 
Cutina 
GMS 
Aerosil 
200 
PVP K 
90 
Ethyl 
cellulose 
Total 
weight 
A1 336 672 ------  ------ ----- ------ 1008 
A2 336 840 ------  ------ ----- ------ 1176 
A3 336 1008 ------  ------ ----- ------ 1344 
G1 336 ------ ------ 1008 ------ ----- ------ 1344 
H1 336 ------ 672  ------ ----- ------ 1008 
H2 336 ------ 840  ------ ----- ------ 1176 
H3 336 ------ 1008  ------ ----- ------ 1344 
H4 336 ------ 1008  ------ ------ 168 1512 
H5 336 ------ 1008  ------ ----- 336 1680 
H6 336 ------ 1008  ------ 336 ------ 1680 
H7 336 ------ 1008  100.8 ----- ------ 1444.8 
H8 336 ------ 1008  100.8 336 ------ 1780.8 
H9* 336 ------ 1008  100.8 ----- ------ 1444.8 
H10* 336 ------ 1008  100.8 ----- ------ 1444.8 
*) Different methods of preparation 
 
Equipment 
Mettler Toledo electric balance, model MS 104S/01 (Mettler Toledo, 
Switzerland); Hanson dissolution tester, model SR8-Plus (Hanson, 
USA); magnetic stirrer (IKA Labortechnik, Germany); Shimadzu 
Spectrophotometer, model UV-2450 UV-VISIBLE spectrophotometer 
and Fourier Transform Infrared spectrophotometer, model FT-IR-
8400 (Shimadzu, Japan); Heraeus oven, model UT 6200; (Heraeus, 
Germany); Stability cabinet (Luwa Environmental Specialties LLC, 
USA); Microscope connected with digital camera (Microvision, 
France); Scanning electron microscope, model JSM-5300 and ion 
sputtering device, model JFC-1100E (Jeol, Japan). 
Preparation of ranitidine hydrochloride floating micro 
particulates (RFM) 
A total of 12 formulations were prepared according to the following 
procedure. A calculated amount of the selected lipid was melted in a 
stainless steel pan kept in an oven at 5 °C above its melting point. RH 
was sieved from 500 µm sieve and mixed with other excipients in a 
plastic bag for 3 min, then added to the molten lipid. The mixture was 
mixed using spatula until homogeneity is reached then mixing was 
continued till the mass congealed and reached room temperature. The 
mass was then sieved (850 µm) and the granules were then collected 
and kept in airtight glass bottles with a desiccant at room temperature. 
The drug to lipid ratios used to prepare the different formulations were 
1:2, 1:2.5 and 1:3. Different release retarding agents were added 
(Aerosil® 200, PVP k90 and ethyl cellulose) with different drug ratios; 
0.3:1, 0.5:1 and 1:1 (table 1). 
The effect of inclusion of Aerosil® in RFM was investigated following 
different techniques. H7 was produced using the same procedure as 
other formulations, while in H9 Cutina® HR was mixed with 
previously sieved Aerosil® 200, and then melted together forming a 
gel mass. Subsequently, pre-sieved ranitidine hydrochloride was 
added and granulated, and then sieved from 850-micron sieve. H10 
was prepared by sieving Aerosil® 200 through 250 µm sieve and 
separately sieve ranitidine hydrochloride from 710 µm sieve. 
Subsequently, mixing both of them for 3 min, re-sieving from 500 µm 
sieve, and finally granulation using melted Cutina® HR followed by 
sieving from 850 µm sieve. 
Characterization of micro-particulates 
Sieve analysis 
Ranitidine hydrochloride micro particulates (RHM) were subjected to 
shaking using a set of descending sieves till constant weight of micro-
particulates is present on each sieve. RHM collected on each sieve 
were accurately weighed and the percent weights of RHM retained in 
each range were computed to characterize the size distribution of the 
formed microparticulate. 
% Weight of RHM = Weight of RHM in this size range
Total weight of RHM  X 100 
Bulk density (ρ bulk) 
It is the ratio of the total mass of powder to the bulk volume of 
powder. It was measured by pouring the weighed powder into a 
measuring cylinder and the volume was noted. It is calculated as 
follows and expressed in g/ml. 
ρ bulk = (M)/(V0) 
Where M is the mass of powder and Vo is the bulk volume of the 
powder.  
Tapped density (ρ tapped) 
It is the ratio of the total mass of powder to the tapped volume of 
powder. The tapped volume was measured by tapping the powder to 
constant volume [13]. It is calculated as follows and expressed in g/ml. 
ρ tapped = (M)/(Vt) 
Where M is the mass of powder and Vt is the tapped volume of the 
powder.  
Angle of repose 
The powder mixture was allowed to flow through a funnel fixed to 
a stand at a definite height. The angle of repose was then calculated 
by measuring the height and radius of the heap of the powder 
formed. The angle of repose θ was calculated from the following 
equation:  
 
Where h is the height of the granules forming the cone (cm) and r is 
the radius of the granules base in (cm).  
Carr’s compressibility index and Hausner ratio 
The compressibility index and the Hausner ratio were determined by 
measuring both the bulk volume and the tapped volume of powder. 
The compressibility index and Hausner ratio indicate the ease with 
which a material can be induced to flow and may be calculated using 
measured values for bulk density (ρbulk) and tapped density (ρtapped) 
as follows [13]:  
Compressibility Index = 100 × ρ tapped − ρbulk
ρ tapped 	 
Hausner Ratio =  
ρ tapped
ρ bulk  
Where ρtapped  and ρbulk  are the tapped and bulk density, respectively.  
Ranitidine hydrochloride content 
An accurate quantity of RFM, equivalent to 5 mg ranitidine 
hydrochloride was transferred to 500 ml volumetric flask. About 200 
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ml of water was added and heated to 80˚C with mixing for 30 min, 
allowed to cool to room temperature while sonicated for another 30 
min. The drug solution was completed to 500 ml with water, and the 
solution was filtered through Whatman filter paper no. 50. The 
sample was analyzed for drug content by UV spectrophotometry at 
313 nm, and the concentrations of ranitidine hydrochloride were 
determined by using the equation:  
% − Drug	content  Drug	content	mg ∗ 100
Label	claim	mg
 
In vitro release study 
In vitro release tests were carried out using USP dissolution tester 
apparatus II (rotating paddle). An accurately weighed amount of RH-
loaded micro particulates equivalent to 336 mg RH was added to 900 
ml 0.1 N HCl release medium kept at 37±0.5˚C and stirred at 50 rpm. 
Samples (15 ml each) were withdrawn at predetermined time intervals 
(1, 2, 4, 6 and 8 h) and filtered using Whatman filter paper no. 50. Each 
sample was replaced by an equivalent amount of blank dissolution 
medium maintained at 37 ˚C. The samples were analyzed 
photometrically at 314 nm. Ranitidine hydrochloride concentration 
was computed using a standard calibration curve. All release tests were 
run in triplicates and data were recorded as the mean values±SD. 
Evaluation of drug release 
Percentage dissolution efficiency (%DE) of a pharmaceutical dosage 
form can be used to characterize drug release profiles. DE is defined 
as the area under the dissolution curve up to a certain time, t, 
expressed as a percentage of the area of the rectangle described by 
100% dissolution. DE can be calculated by the following equation:  
 
where y is the %-drug dissolved at time t [14]. In this study, all 
dissolution efficiencies were obtained with t equal to 8 h. The areas 
under the curve (AUC) were calculated for each dissolution profile by 
the trapezoidal method. It is generally preferable to choose a time 
interval corresponding to 70–90% dissolution unless one wishes to 
compare an early part of the dissolution curve. Normally t1=0 for 
tablets or granules where there is no lag phase. For a capsule product, 
t1 can be set to the period corresponding to the disintegration of the 
capsule shell. 
In vitro buoyancy studies 
The floating abilities of micro-particulates were determined by adding 
an accurately weighed 100 mg micro particulates in 20 ml pre-warmed 
0.1 N HCl containing 0.1 M NaCl, followed by shaking horizontally at a 
speed of 100 cycles/min using a mechanical shaker apparatus for 12 h 
at 37 ˚C [15]. The percent-floating micro particulates was calculated by 
dividing the number of floating micro particulates (nt) by the initial 
total number tested (n initial) as follows:  
nt
ninitial
	 100 
Where nt is the number of floating micro particulates, and ninitial is the 
total number of micro-particulates.  
Scanning electron microscopy (SEM) 
The surface morphology of selected beads was visualized by scanning 
electron microscopy. The sample for SEM was prepared by sticking the 
beads on a double-sided adhesive tape, stuck to an aluminum stub. The 
stubs were then coated with a thin layer of gold (~300A˚) for 30 
seconds at 30 W. The samples were then randomly scanned with 25Kv 
power, using magnifications from 150 to 2000 times. 
Differential scanning calorimetry (DSC) 
The DSC measurements were performed using 3 mg samples placed 
in sealed aluminum pans, before heating under nitrogen flow (20 
ml/min) at heating rate 10˚C/min, over the temperature range of 35˚C 
to 300 ˚ C. An empty aluminum pan was used as a reference. DSC of the 
pure ranitidine hydrochloride, lipids (hydrogenated castor oil or 
glyceryl behenate), and floating micro particulates were compared 
with each other. 
Infrared spectroscopy 
The IR spectra were performed between 3000 and 400 cm-1 using KBr 
disks (about 2 mg sample in 200 mg KBr). Acquired spectra were first 
corrected for background based on the signal recorded for the same 
KBr alone. The examination was performed for pure ranitidine 
hydrochloride, selected lipids, selected examples of floating micro 
particulates.  
Stability studies 
Samples of selected formulations were packed in a sealed HDPE 
bottles with a desiccant, packed into aluminum pouch then were 
stored in stability chambers at 40˚C and relative humidity 75%. The 
samples were withdrawn periodically and evaluated for the drug 
content, in vitro drug release, and in vitro buoyancy using the same 
methods previously described. 
RESULTS AND DISCUSSION 
Preparation of ranitidine hydrochloride floating micro particulates  
In the preliminary studies beeswax and stearic acid failed to produce 
solid multi-particulates, forming instead a sticky mass that clogs the 
sieve pores during sieving process. Based on preliminary studies, 
Cutina® GMS, Cutina® HR, and Compritol® ATO 888 were selected as 
the lipid-bases for further studies.  
Particle sizes analysis 
Results of size analysis of RFM are listed in table 2. It is obvious from 
these results that 90% or more of the prepared micro particulates 
have the particle size of less than 710 µm. The cumulative %-
undersize distribution data are summarized in table 3. More than 
50% of the floating micro particulates were less than 355 µm and 
from 75% to 85% were<500. 
 
Table 2: Size distributions (%) of ranitidine hydrochloride microparticulates prepared by melt granulation method (n=3) (average±SD) 
Formula <0.106 mm 0.106-0.355 mm 0.355-0.5 mm 0.5-0.71 mm >0.710 mm 
H1 26.0±0.26 27.4±0.26 22.1±0.17 16.2±0.13 4.9±0.09 
H2 27.1±0.17 27.2±0.26 21.8±0.1 15.3±0.05 6.0±0.05 
H3 32.7±1.05 33.8±0.17 17.2±0.09 8.8±0.04 1.7±0.04 
H4 25.6±0.3 33.09±0.1 17.2±0.08 14.33±0.05 4.0±0.18 
H5 26.2±0.2 34. 7±0.1 20.5±0.07 9.7±0.04 2.8±0.06 
H6 29.1±0.26 32.4±0.1 21.4±0.12 11.3±0.05 3.7±0.06 
H7 19.9±0.17 35.0±0.2 24.1±0.09 14.2±0.03 4.9±0.04 
H8 24.7±0.26 31.6±0.17 24.0±0.11 14.1±0.12 3.0±0.11 
H9 21.4±0.4 32.1±0.38 22.9±0.06 14.4±0.09 5.7±0.04 
H10 30.3±0.36 35.8±0.17 20.1±0.13 10.5±0.09 3.3±0.04 
A1 20.1±0.44 34.0±0.92 21.0±0.62 16.14±0.07 2.9±.03 
A2 21.7±0.36 36.2±0.44 25.6±0.26 14.1±.09 2.3±0.06 
A3 17.1±0.46 42.3±0.2 11.9±0.09 12.9±0.07 3.7±0.03 
G3 23.6±0.61 37.0±0.17 23.2±0.15 11.3±0.08 2±0.21 
The size distribution of all formulations indicated that the prepared formulations resulted in a reasonably small floating micro particulates (table 3). 
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Table 3: Cumulative percent undersize distributions of ranitidine HCl microparticulates prepared by melt granulation method (n=3) 
(average±SD) 
Formula <0.106 mm <0.355 mm <0.5 mm <0.710 mm <0.85 mm 
H1 26.0±0.26 53.4±0.53 75.6±0.44 91.8±0.31 96.7±0.26 
H2 27.1±0.17 54.3±0.2 76.1±0.17 91.4±0.18 97.4±0.22 
H3 32.7±1.05 66.5±1.2 83.7±1.13 92.5±0.14 94.2±0.14 
H4 25.6±0.3 58.7±0.25 75.9±0.28 90.2±0.24 94.2±0.15 
H5 26.2±0.2 60.9±0.17 81.4±0.18 91.1±0.18 93.9±0.17 
H6 29.1±0.26 61.5±0.26 82.9±0.16 94.2±0.15 97.9±0.16 
H7 19.9±0.17 54.9±0.26 79±0.35 93.2±0.34 98.1±0.38 
H8 24.7±0.26 56.3±0.2 80.3±0.26 94.4±0.24 97.4±.25 
H9 21.4±0.4 53.5±0.05 76.4±0.11 90.8±0.02 96.5±0.03 
H10 30.3±0.36 66.1±0.44 86.2±0.55 96.7±0.58 100.0±0.56 
A1 20.1±0.44 54.1±0.61 75.1±0.78 91.2±0.75 94.1±0.76 
A2 21.7±0.36 57.9±0.17 83.5±0.26 97.6±0.26 100.0±0.27 
A3 17.1±0.46 59.4±0.56 71.3±.48 84.2±0.54 87.9±.53 
G3 23.6±0.61 60.6±0.7 83.8±0.83 95.1±0.82 97.1±0.98 
 
Flow properties 
The flow properties of pure drug and samples of formulated floating 
micro particulates were evaluated by measuring the angle of repose, 
Hausner ratio and Carr’s compressibility index as shown in table 4. 
Hausner ratios and Carr’s compressibility indices ranged from 1.17 to 
1.289 and 14.54 to 22.4%, respectively. The results are acceptable for 
granules and in agreement with previous studies [13]. It has been 
reported that material would be considered showing excellent flow 
properties when having an angle of repose equal to or less than 40˚. 
All formulations showed excellent flow ability as represented in 
terms of angle of repose (≤40°) [16]. Furthermore, it was obvious 
from the results in table 4 that all the prepared floating micro 
particulates had similarly bulk and tapped densities. 
  
Table 4: Bulk density, tapped density and flow properties of ranitidine hydrochloride floating micro particulates samples prepared by 
method melt granulation in terms of angle of repose, Hausner’s ratio and Carr’s compressibility index of the prepared formulations, as 
compared with ranitidine hydrochloride powder (n=3) (average±SD) 
Sample Bulk density (g/ml) Tapped density (g/ml) Angle of repose 
(degree) 
Hausner’s ratio Carr’s index (%) 
H1 0.43±0.01 0.51±0.02 34.88 °±1.31 1.188±0.02 15.85±1.52 
H2 0.46±0.02 0.55±0.02 37.48 °±0.85 1.196±0.04 16.36±2.97 
H3 0.43±0.01 0.54±0.01 36.57 °±0.44 1.256±0.05 20.37±2.92 
H4 0.42±0.01 0.53±0.01 37.9 °±1.45 1.262±0.05 20.75±3.38 
H5 0.42±0.03 0.53±0.01 34.59 °±1.64 1.262±0.06 20.75±4.03 
H6 0.45±0.01 0.58±0.02 33.69 °±1.46 1.289±0.05 22.40±2.88 
H7 0.44±0.02 0.53±0.01 29.7 °±1.04 1.205±0.03 16.98±2.09 
H8 0.43±0.02 0.52±0.01 29.7 °±2.22 1.209±0.05 17.31±3.72 
H9 0.46±0.01 0.55±0.01 32.83 °±1.42 1.196±0.02 16.36±1.68 
H10 0.47±0.01 0.55±0.02 32.4 °±1.67 1.170±0.06 14.54±4.44 
A1 0.39±0.01 0.47±0.01 38.42 °±1.2 1.205±0.06 17.02±3.9 
A2 0.38±0.01 0.46±0.02 33.65 °±0.62 1.211±0.05 17.39±3.77 
A3 0.39±0.02 0.47±0.01 36.13 °±1.88 1.205±0.06 17.02±4.13 
G3 0.37±0.02 0.46±0.03 37.02 °±1.45 1.243±0.2 19.56±1.56 
Ranitidine HCl 0.26±0.02 0.47±0.01 50.71 °±0.76 1.808±0.15 44.44±4.79 
 
Content of ranitidine hydrochloride in the prepared floating 
micro particulates 
The drug content of the various floating formulations was observed 
to be in the range 100±7%, which complies with the Pharmacopeial 
requirements [17]. 
In vitro release studies 
Ranitidine hydrochloride concentrations (mg/100 ml) over the 
whole dissolution rate study of the different formulations were 
plotted against time and the results are presented in fig. 1-5. 
Incorporation of different types and percentages of Compritol® (A1, 
A2, A3) and hydrogenated castor oil (H1, H2 and H3) in the floating 
lipid matrix highly affected the release of ranitidine from the floating 
micro particulates. It could be observed from fig. 1 that floating micro 
particulates made of Compritol® (A1, A2, A3) showed a relatively 
higher release properties compared to those made of hydrogenated 
castor oil (H1, H2, H3). This finding is in accordance with previous 
studies, e. g. [1]. On the other hand, Zantac® tablets exhibited fast drug 
release amounting to 100% in about 30 min. 
It was also observed that increasing the proportion of the fatty 
component (1:2, 1:2.5 and 1:3) was accompanied by proportional 
retardation in ranitidine HCl release. This behavior was encountered 
with both Compritol® and hydrogenated castor oil based floating 
RFM. Furthermore, it could be concluded that hydrogenated castor oil 
showed higher affinity to retard RH release, compared to Compritol®; 
however, the retardation in both fatty bases was a function of their 
proportions in the respective formulations (fig. 1). 
 
Fig. 1: In vitro release data of ranitidine HCl from floating micro 
particulates prepared using compritol® (A1, A2, A3) or 
hydrogenated castor oil (H1, H2, H3) in 0.1 N HCl (n=3) 
(average±SD) 
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The release effect of several additives incorporated in the prepared 
floating RFM, namely, ethylcellulose, PVP k90 and Aerosil® 200, was 
investigated. The results are illustrated in fig. 2-5. 
Incorporation of Aerosil® 200 (hydrophilic colloidal silicon dioxide) 
in the floating micro particulates (H7, H9, H10) affected the release of 
ranitidine HCl only in early stage (1 and 2 h), as it could decrease 
burst release of the formulation (fig. 2). The decrease in release in the 
early time points could be due to the interaction of similar groups on 
the surface of different particles of colloidal silicon dioxide via 
chemical bonds with each other to form connecting bridges. This, in 
turn, leads to the immobilization of dissolution medium and gel layer 
formation which could reduce burst effect at early points. The 
relatively slight increase in dissolution afterward could be due to the 
disintegration effect of hydrophilic colloidal silicon dioxide [18]. 
The effect of ethyl cellulose as a release retarding agent is illustrated in 
fig. 3. Formulations containing ethyl cellulose (H4 and H5) showed a 
relatively slower drug release compared with the formulation devoid of 
ethyl cellulose (H3). The retardation is mainly observed starting from 2 
h till 8 h following the initiation of the release study. Contrary to what 
was expected, the lower proportion of ethyl cellulose (H4) resulted in a 
relatively greater retarding effect compared with (H5) containing the 
higher proportion of ethyl cellulose (fig. 3). It could be suggested that 
increasing the proportion of ethyl cellulose (H5) may result in 
increasing the porosity of the prepared particles resulting in enhanced 
release compared with (H4) [11]. 
 
 
Fig. 2: In vitro release data of ranitidine HCl from floating 
microparticles prepared using hydrogenated castor oil with 
and without the Aerosil® 200 (H3, H7, H9, H10) in 0.1 N HCl 
(n=3) (average±SD) 
 
 
Fig. 3: In vitro release data of ranitidine HCl from floating micro 
particulates prepared using hydrogenated castor oil with and 
without the addition of ethylcellulose (H3, H4, H5) in 0.1 N HCl 
(n=3) (average±SD) 
Fig. 4 shows the effect of PVP K90 on the release of ranitidine HCl 
from floating micro particulates prepared using hydrogenated castor 
oil (H6), pointing out a remarkable reduction in release pattern of the 
drug from the floating micro particulates. The combined effect of 
Aerosil® and PVP K90 as retarding agents is shown in fig. 5. H8 
showed a relatively lower release of the drug compared to H3. 
However, no remarkable difference could be observed between the 
combined effect (H8) and the single effect of either Aerosil® alone 
(H4) or PVP alone (H6) (fig. 1-5). 
Dissolution efficiency 
The dissolution profiles were characterized by the calculated 
dissolution efficiency (DE%). The observed values range from 64.5-
93.4%. The minimum drug release and consequently maximum 
retardation were observed with Cutina® HR (H6), whereas maximum 
drug release and minimum retardation were in the case of glyceryl 
monostearate formulation (G1). 
 
 
Fig. 4: In vitro release data of ranitidine HCl from floating micro 
particulates prepared using hydrogenated castor oil with and 
without the addition of PVP K90 (H3, H6) in 0.1 N HCl (n=3) 
(average±SD) 
 
 
Fig. 5: In vitro release data of ranitidine HCl from floating micro 
particulates prepared using hydrogenated castor oil with and 
without the addition of PVP K90 and Aerosil® 200 combinations 
(H3, H8) in 0.1 N HCl (n=3) (average±SD) 
 
In vitro buoyancy studies 
The floating capability of the prepared micro particulates was 
performed by the in vitro buoyancy studies. The floating lag time is the 
time taken by RH multi-particulates to appear to the surface of the 
dissolution medium. The micro-particulates floated immediately on the 
medium, and the floating lag time (min.) was zero for all the tested 
formulations. The percent of floating multi-particulates of different 
formulations after 12 h ranged between 75% (G1) and 99.9% (H7).  
The absence of floating lag time is ideal to prevent dosage form from 
the transition to the intestine. The absence of lag time could be due to 
the low density of formulations. The percent of microparticulate 
floating at the end of buoyancy studies was almost 100% in all 
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formulations with the exception of formulations prepared using 
glyceryl monostearate (G1). The observed overall higher floating 
tendency (>98%) of the prepared formulations render them good 
candidates for further investigations [19]. 
Scanning electron microscope 
The surface morphology of some selected formulations as examined 
by SEM is shown in fig. 6-8. Microparticulates exhibited in general 
pores of variable intensities. The surface of (H9) appears to show 
flakes that could be of silicon dioxide (Aerosil® 200). 
 
 
Fig. 6: Photographs showing surface morphology of ranitidine hydrochloride micro particulates (formula H5) in different magnifications 
 
 
Fig. 7: Photographs showing surface morphology of ranitidine hydrochloride micro particulates (H6) in different magnifications 
 
 
Fig. 8: Photographs showing surface morphology of ranitidine hydrochloride micro particulates (H9) in different magnifications 
 
Fourier transformer infra-red spectroscopy (FTIR) 
The infra-red spectra (fig. 9) of RH pointed out the characteristic peak 
at 2510 cm−1(attributed to the N+and–H bond in protonated tertiary 
amine group), a prominent IR absorption band at 1620 cm−1 due to 
stretching vibration of C=N of amine group, and another 
characteristic peak of N=O at 1421.14 cm−1. 
The IR spectra (Data not shown) of Cutina® HR and all formulations 
proved the presence of a strong band at 1746 cm-1 related to C=O 
(ester) group. Furthermore, the spectra indicated that neither new IR 
absorption bands characteristic of complex formation nor 
disappearance of bands was observed. Besides, no shift or broadening 
of characteristic bands was observed, indicating the compatibility of the 
used excipients with the active ingredient [20]. 
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Fig. 9: The infra-red spectra of ranitidine hydrochloride (A), 
Cutina HR (B), H5 floating microparticulates (C), H6 floating 
microparticulates (D), and H9 floating microparticulates (E) 
 
Differential scanning calorimetry (DSC) 
DSC scans of the individual components and the RFM were performed 
(fig. 10). The results showed that RH exhibited a sharp endothermic 
peak at 145.05 °C, Cutina® HR showed an endotherm at 77.123 °C, and 
PVP K90 showed a broad endotherm at 85.9 °C while ethyl cellulose 
did not display any thermal event in the examined temperature range. 
The DSC curve of H5 microsphere showed the endothermic peak of 
the carrier around 85.7 °C and the endothermic peak of the drug at 
143.9 °C. The DSC curve of H6 microsphere showed the endothermic 
peak of the carrier around 82.5 °C and the endothermic peak of the 
drug at 144.9 °C. The DSC curve of H7 microsphere showed the 
endothermic peak of the carrier around 86.1 °C and the endothermic 
peak of the drug at 146.16 °C. It could be concluded from the DSC 
results that there was no appreciable interaction between the drug 
and the other ingredients as indicated by the presence of the 
characteristic peaks of the pure drug and the individual additives 
almost in the same temperature range observed in the formulated 
micro particulates. 
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Fig. 10: Differential scanning calorimetry (DSC) thermograms of 
ranitidine hydrochloride (A), Cutina HR (B), PVP K90 (C), ethyl 
cellulose (D), ranitidine floating microparticulates H5 (E), 
ranitidine floating microparticulates H6, and ranitidine floating 
microparticulates H9 (G) 
 
Stability studies  
To assess the formulation stability, the accelerated stability 
studies were performed for 6 mo. The floating micro particulates 
of formulae H5, H6 and H9 were stored in 30 ml HDPE bottles 
properly capped and placed in an aluminum pouch. Stability 
studies were performed at 40±2 °C/75 % RH according to the ICH 
guidelines [21]. The stability studies in terms of floating time, 
assay and drug release were carried out and samples were 
examined after 0, 1, 3, and 6 mo. Formulations were evaluated for 
any physical or chemical changes after storage. 
Only after 6 mo, there was a slight difference in the in vitro dissolution 
profiles, compared to zero time (fig. 11), an increase in DE% of H5 and 
H6 was observed. On the other hand, the dissolution efficiency of H9 
was decreased (from 71.24 to 69.3) indicating slight drug release 
retardation in comparison with zero time. The observed DE% values 
after storage were 78.2, 73.7, and 69.3% for H5, H6, and H9 
respectively. The corresponding values for the freshly prepared 
microparticles were 70.5, 64.6, and 71.24%. In-vitro drug release 
profile of ranitidine floating micro particulates after 6 mo at 40 ̊C/75 
%RH was compared with drug release profile of the same formulation 
at zero time. The data obtained from in vitro drug release was used to 
determine the similarity factor and dissimilarity factor between 
different formulations. The similarity factor (f2) and dissimilarity 
factor Q1 (f1) were calculated using the formulas (Shah et al., 1998).  
 
Where n is the number of time points, Rt and Tt are the dissolutions 
of the formulation at zero time and after 6 mo at 40 ̊C/75 %RH, 
respectively. In general, f2 values higher than 50 (50-100) shows 
the similarity of the dissolution profiles of H5and H9 and 
dissimilarity of H6.  
 
Fig. 11: In vitro release data of ranitidine HCl from floating 
micro particulates after 6 mo in accelerated stability study (H5, 
H6, H9) in 0.1 N HCl (n=3) (average±SD) 
 
Drug content and %-floating 
The recorded drug content values after 6 mo were 95.4, 93.8, and 92.8 
for H5, H6, and H9; compared to 102.0, 107.4, and 99.8% at zero time, 
respectively. The corresponding values for %-floating were 95.5, 
96.5, and 99.4; compared to 99.1, 99.8, and 99.6% at zero points, for 
H5, H6, and H9, respectively. The results revealed insignificant 
changes in microparticle properties over 6 mo. 
CONCLUSION 
1. The prepared microparticles exhibited optimum particle size 
(more than 90% of the prepared microparticles are less than 710 µm), 
good compressibility, and flow properties (angle of repose ≤40 °).  
2. RFM containing Compritol® showed a relatively higher release 
properties compared to hydrogenated castor oil.  
3. Increasing the proportion of the fatty component was 
accompanied by retardation in RH release.  
4. The percent-floating of RFM was almost 100% in all formulations 
with the exception of formulations prepared using glyceryl 
monostearate.  
5. FT-IR and DSC indicated the compatibility of the excipients with 
RH. Stability results revealed an insignificant change in RFM 
properties over 6 mo. 
6. Stability studies of the selected formulation H5 and H9, at 
40 ̊C/75 %RH showed no significant changes in release profile (with 
f2 value at 6 mo of 54, 63, respectively taking zero time as reference). 
Furthermore, the main physical parameters, such as flowability, in 
vitro buoyancy, total drug content, and drug release, exhibited similar 
stability upon aging. H5 and H9 was stable for up to 6 mo at 40 
°C/75% RH.  
7. Although H6 exhibited good physical and chemical parameters at 
zero time but stability study showed significant changes in release 
profile after 6 mo at 40 C̊/75 %RH (with an f2 value of 49).  
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